Home
IDYA
IDYA News

Latest IDEAYA Biosciences Inc. (IDYA) News on March 29, 2025

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a day ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

PR Newswire

3 days ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform

Insider Monkey

24 days ago

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform

MT Newswires

a month ago

IDEAYA Biosciences, ATTMOS Collaborate to Advance Small Molecule Discovery for Undruggable Oncology Targets

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

PR Newswire

a month ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

a month ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

Zacks

a month ago

Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)

MT Newswires

a month ago

RBC Lowers Price Target on IDEAYA Biosciences to $57 From $61, Keeps Outperform, Speculative Risk

MT Newswires

a month ago

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

Zacks

a month ago

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

MT Newswires

a month ago

IDEAYA Biosciences Q4 Loss Widens, Revenue Rises

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PR Newswire

a month ago

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

PR Newswire

a month ago

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

Zacks

2 months ago

All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy

MT Newswires

2 months ago

IDEAYA Biosciences Appoints Joshua Bleharski as Finance Chief

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

PR Newswire

2 months ago

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

Insider Monkey

2 months ago

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

PR Newswire

2 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Simply Wall St.

2 months ago

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

PR Newswire

3 months ago

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

MT Newswires

3 months ago

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

PR Newswire

3 months ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

3 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

IDEAYA Biosciences Gets Move-Forward Dose for Phase 2/3 Darovasertib-Crizotinib Trial

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR Newswire

3 months ago

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR Newswire

3 months ago

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

Simply Wall St.

3 months ago

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

PR Newswire

4 months ago

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

PR Newswire

4 months ago

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

MT Newswires

4 months ago

IDEAYA Biosciences Nominates IDE892 as Development Candidate

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

PR Newswire

4 months ago

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

PR Newswire

4 months ago

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey

4 months ago

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

PR Newswire

4 months ago

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

PR Newswire

5 months ago

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

MT Newswires

5 months ago

IDEAYA Biosciences Exercises Option to Develop Biocytogen's Potential Cancer Treatment

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

PR Newswire

5 months ago

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Business Wire

5 months ago

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

Zacks

5 months ago

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

MT Newswires

5 months ago

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, $27 Price Target

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

Simply Wall St.

5 months ago

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

PR Newswire

5 months ago

/C O R R E C T I O N -- IDEAYA Biosciences, Inc./

MT Newswires

5 months ago

IDEAYA Biosciences Q3 Loss Narrows

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

5 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

MT Newswires

5 months ago

IDEAYA Biosciences Secures FDA Approval for IDE275's Investigational New Drug Application

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

PR Newswire

5 months ago

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

MT Newswires

5 months ago

IDEAYA Biosciences Reports 'Positive' Interim Phase 1 Data for Cancer Drug; Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

PR Newswire

5 months ago

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

MT Newswires

5 months ago

UBS Initiates IDEAYA Biosciences With Buy Rating, $50 Price Target

MT Newswires

5 months ago

Cantor Fitzgerald Initiates IDEAYA Biosciences at Overweight

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

PR Newswire

6 months ago

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

Clinical Trials Arena

6 months ago

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans

MT Newswires

6 months ago

Wedbush Trims Price Target on IDEAYA Biosciences to $52 From $54, Keeps Outperform Rating

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires

6 months ago

Ideaya Biosciences Says Phase 2 Darovasertib Trial Showed 'Clinically Meaningful' Results

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

PR Newswire

6 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

PR Newswire

6 months ago

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

PR Newswire

6 months ago

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PR Newswire

7 months ago

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

Simply Wall St.

8 months ago

News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Simply Wall St.

8 months ago

IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

MT Newswires

8 months ago

Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $60, Maintains Outperform Rating

MT Newswires

8 months ago

IDEAYA Biosciences Shares Gain After Company Reports Q2 Net Loss

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

PR Newswire

8 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

8 months ago

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

MT Newswires

8 months ago

IDEAYA Biosciences, Biocytogen Agree to Option, License Deal for Solid Tumors Treatment Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

8 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Business Wire

8 months ago

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

PR Newswire

8 months ago

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

PR Newswire

8 months ago

IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

Zacks

8 months ago

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%

MT Newswires

8 months ago

Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts

Simply Wall St.

8 months ago

Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts

MT Newswires

9 months ago

JPMorgan Raises Price Target on IDEAYA Biosciences to $69 From $65, Maintains Overweight Rating

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire

9 months ago

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Zacks

9 months ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

MT Newswires

9 months ago

RBC Raises Price Target on IDEAYA Biosciences to $61 From $53, Keeps Outperform, Speculative Risk

MT Newswires

9 months ago

IDEAYA Biosciences Prices $263 Million Public Offering

IDEAYA Announces Pricing of Public Offering

PR Newswire

9 months ago

IDEAYA Announces Pricing of Public Offering

MT Newswires

9 months ago

IDEAYA Biosciences Plans to Sell Shares, Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire

9 months ago

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Zacks

9 months ago

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Company News for July 9, 2024

Zacks

9 months ago

Company News for July 9, 2024

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

Zacks

9 months ago

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment

Clinical Trials Arena

9 months ago

IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

Investopedia

9 months ago

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

IDEAYA Biosciences Soars on Cancer Drug Study Results

Investopedia

9 months ago

IDEAYA Biosciences Soars on Cancer Drug Study Results

MT Newswires

9 months ago

Wedbush Raises Price Target on IDEAYA Biosciences to $56 From $52, Maintains Outperform Rating

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March

Investor's Business Daily

9 months ago

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March

MT Newswires

9 months ago

Ideaya Biosciences Reports Positive Results for Potential Non-Small Cell Lung Cancer Treatment -- Shares Rise Pre-Bell

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

PR Newswire

9 months ago

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

MT Newswires

9 months ago

Mizuho Securities Initiates IDEAYA Biosciences at Outperform With $50 Price Target

Share on Social Networks: